FDA Approves Itvisma for Spinal Muscular Atrophy

MONDAY, Dec. 8, 2025-- The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in the survival motor neuron...